Business News • PR NewsWire • iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for Discovery and Development of Cancer Immunosuppression Targets

iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for Discovery and Development of Cancer Immunosuppression Targets

iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for Discovery and Development of Cancer Immunosuppression Targets

GOSSELIES, Belgium, Dec. 8, 2014 /PRNewswire/ -- iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan...

View More : http://www.prnewswire.com/news-releases/iteos-therapeutics-announces-license-and-collaboration-with-pfizer-inc-for-disco...

Releted News by prnewswire

Auto Wiring Harness Market Size at $43.5 Billion in 2015, Forecasts a New Global and China Industry Research Report

Global Temperature Sensors (Bimetallic, IC, Thermistor, RTD, Thermocouple, IR, Fiber Optic) Market - Forecasts to 2020

Residence Inn San Diego Oceanside Undertakes Massive Renovation

Guaranteed Returns Names New President And CEO As It Plans For Future